中文
中文

以患者需求为核心,驱动细胞免疫治疗创新,实现癌症可控化并最终治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.

2019
  • 0
Streamlined Low-Input Transcriptomics through EASY-RNAseq.     
J Mol Biol. 431(24):5075-5085. (PMID: 31491452)
Zhou Y., Xu H., Wu H., Yu H., Zhou P., Qiu X., Zheng Z., Chen Q., Xu F., Li G., Zhou J., Cheng G., He W., Zou L, Wan Y. (2019) 

 TCR repertoire and CDR3 motif analyses depict the role of αβ T cells in Ankylosing spondylitis.  
EBioMedicine. (19)30474-8. (*: Corresponding authors, PMCID: PMC6796593)
Zheng M., Zhang X., Zhou Y., Tang J., Han Q., Zhang Y., Ni Q., Chen G., Jia Q., Yu H., Liu S., Robins E., Jiang NJ., Wan Y.*, Li Q.-J. *, Chen Z.-N.*, Zhu P.* (2019)
03.23
2022
来源:
关键词:
相关阅读

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer